RedHill Biopharma announced that the U.S. Patent and Trademark Office, or USPTO, issued a new patent, U.S. Patent No. 11,878,011, covering Talicia as a method for eradicating Helicobacter pylori regardless of patient Body Mass Index, or BMI. This new patent is expected to provide protection for Talicia until May 2042.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RDHL:
- RedHill Biopharma: Opaganib, RHB-107 show ‘robust synergistic effect’ in study
- RedHill Biopharma regains Nasdaq compliance
- RedHill Biopharma announces new non-dilutive external funding
- Biotech Alert: Searches spiking for these stocks today
- RedHill Biopharma announces FDA grant of 5-year market exclusivity for Talicia